Skip to main content

Published locations for RA: No significant change in efficacy and safety after adalimumab to CT-P17 switch

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. RA: No significant change in efficacy and safety after adalimumab to CT-P17 switch

User login

  • Reset your password
  • /content/ra-no-significant-change-efficacy-and-safety-after-adalimumab-ct-p17-switch
  • /rheumatology/article/243484/rheumatoid-arthritis/ra-no-significant-change-efficacy-and-safety-after